CLIN
Jerry Nick, MD (he/him/his)
Medicine
National Jewish Health
Jennifer Guimbellot
Pediatrics
Arkansas Children's Hospital/Arkansas Children's Research Institute
While therapy with elexacaftor/tezacaftor/ivacaftor (ETI) has well-established benefits in larger cohorts, some individuals appear to have much less response, and long-term consequences of these modulators are still to be determined. The mechanisms of ETI response are complicated and not fully understood. This symposium will present current findings on the long-term effects of ETI on inflammation and clinical outcomes, and explore the potential for ETI pharmacokinetics to determine response to treatment.
Speaker: Jennifer Guimbellot – Arkansas Children's Hospital/Arkansas Children's Research Institute
Speaker: Paul M. Beringer, PharmD (he/him/his) – University of Southern California
Speaker: Jamie Duckers, MD (he/him/his) – All Wales Adult CF Centre, Cardiff and Vale University Health Board, Cardiff, UK
Speaker: Scott Sagel, MD, PhD – Children's Hospital Colorado/University of Colorado Anschutz Medical Campus